Evidence map›Paper›PMID 26804607›Full record

Trial reportCirculation journal : official journal of the Japanese Circulation Society2016

Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure - Subanalysis of the WARCEF Trial.

Tomoko S Kato, Marco R Di Tullio, Min Qian, Mengfei Wu, John L P Thompson, Douglas L Mann, Ralph L Sacco, Patrick M Pullicino, Ronald S Freudenberger, John R Teerlink and 11 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Circulation journal : official journal of the Japanese Circulation Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. CHAEuropean journal of heart failure · 2016
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Tomoko S KatoDepartment of Medicine, Division of Cardiology, Columbia University Medical Center.
Marco R Di Tullio
Min Qian
Mengfei Wu
John L P Thompson
Douglas L Mann
Ralph L Sacco
Patrick M Pullicino
Ronald S Freudenberger
John R Teerlink
Susan Graham
Gregory Y H Lip
Bruce Levin
Jay P Mohr
Arthur J Labovitz
Conrado J Estol
Dirk J Lok
Piotr Ponikowski
Stefan D Anker
Shunichi Homma
WARCEF Investigators

Funding

Warfarin vs. Aspirin in Reduced Ejection Fraction (WARCEF)U01NS043975 · NINDS · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI HOMMA, SHUNICHI · 2001 to 2010
$43.3M
Warfarin vs Aspirin in Reduced Ejection Fraction -STATU01NS039143 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI THOMPSON, JOHN L · 2001 to 2010
$21.3M
NINDS NIH HHS U01 NS039143NINDS NIH HHS U01-NS-039143NINDS NIH HHS U01 NS043975NINDS NIH HHS U01-NS-043975
6 · The paper itself

Abstract

backgroundHeart failure (HF) patients have a high incidence of new-onset AF. Given the adverse prognostic influence of AF in HF, identifying patients at high risk of developing AF is important. METHODS AND 

resultsThe incidence and factors associated with new-onset AF were investigated in patients in sinus rhythm with reduced LVEF enrolled in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. Analyses involved clinical factors alone (n=2,219), and clinical plus echocardiographic findings (n=1,125). During 3.5±1.8 years of follow-up, 212 patients (9.6% of total cohort) developed AF. In both samples, new-onset AF was associated with age, male sex, White race, and IHD. Among echocardiographic variables, only LAD predicted AF. On multivariate Cox modeling, age (HR, 1.02; 95% CI: 1.00-1.03, P=0.008), IHD (HR, 1.37; 95% CI: 1.02-1.84, P=0.036) and LAD (HR, 1.48; 95% CI: 1.15-1.91, P=0.003) remained associated with AF onset. Patients with IHD, LAD>4.5 cm and age>50 years had a 2.5-fold higher risk of AF than patients without any of these characteristics (HR, 2.52; 95% CI: 1.72-3.69, P<0.0001).

conclusionsAge, IHD and LAD independently predict new-onset AF in HF patients in sinus rhythm, at younger age and smaller LAD than generally believed. This information may be useful to risk-stratify HF patients for AF development, allowing close monitoring and possibly early detection. (Circ J 2016; 80: 619-626).

Indexed as

Atrial FibrillationEchocardiographyHeart FailureAgedAge FactorsAspirinFollow-Up StudiesHumansMiddle AgedStroke VolumeWarfarinAspirinWarfarin

Identifiers

PMID26804607
PMCPMC13285859

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.